This is part 2 in a series on gene therapies. In this paper, we focus on supply chain considerations. We dissect the supply chain topic into a number of components, such as manufacturing, packaging, labeling, logistics, etc. For each component, we discuss how it differs for gene therapies (vs. “traditional” pharmaceutical and biotech therapies) and provide some guidance for commercial strategy development.
